Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Breakthrough drug improves treatment of medulloblastoma in mice February 4, 2025 Understanding the role of genetic variants in male infertility April 14, 2024 Physical activity could help colon cancer survivors match general population survival rates February 24, 2025
Physical activity could help colon cancer survivors match general population survival rates February 24, 2025